Tiotropium improves FEV1 in patients with COPD irrespective of smoking status.

This study evaluated whether the effect of tiotropium on the change in trough forced expiratory volume in 1s (FEV1), vs. placebo, is affected by smoking status. In a 3-month, double-blind study in 31 centres in Portugal, 311 (289 completed) patients were randomised to tiotropium 18 microg once daily or placebo. Baseline mean (standard deviation (SD)) FEV1 was 1.11 (0.39) l in the tiotropium group and 1.13 (0.39) l in the placebo group. Patients had an average smoking history of 55 (25.7) pack-years; 80 (26%) were smokers and 224 (74%) were ex-smokers. The primary end-point was change in morning pre-dose (i.e. trough) FEV1 after 12 weeks. Trough FEV1 at 12 weeks was significantly improved with tiotropium vs. placebo: the difference in means was 102 ml, P=0.0011, 95% confidence interval (CI) (41, 164). The difference in means in smokers was 138 ml, P=0.0105, CI (32, 244); in ex-smokers it was 66 ml, P=0.0375, CI (3, 129). The difference between smokers and ex-smokers was not statistically significant (P=0.6982) and may be due to greater variability and differences in disease severity. The significant improvement in lung function in patients treated with tiotropium vs. placebo in both smokers and ex-smokers suggests that tiotropium is an effective and well-tolerated therapy in chronic obstructive pulmonary disease (COPD), regardless of smoking status.

[1]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[2]  A. Anzueto,et al.  One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. , 2005, Pulmonary pharmacology & therapeutics.

[3]  Aker,et al.  A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation. , 1999, The New England journal of medicine.

[4]  R. Peto,et al.  The natural history of chronic airflow obstruction. , 1977, British medical journal.

[5]  R. Zuwallack,et al.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease , 2002, European Respiratory Journal.

[6]  A H Coulson,et al.  The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. , 1994, American journal of respiratory and critical care medicine.

[7]  C. Lenfant,et al.  Global Initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease , 2006 .

[8]  John L. Hankinson,et al.  Standardization of Spirometry, 1994 Update. American Thoracic Society. , 1995, American journal of respiratory and critical care medicine.

[9]  S. Rennard,et al.  Extended therapy with ipratropium is associated with improved lung function in patients with COPD. A retrospective analysis of data from seven clinical trials. , 1996, Chest.

[10]  D. Mant,et al.  Meta-analysis on efficacy of nicotine replacement therapies in smoking cessation , 1994, The Lancet.

[11]  U. Lalloo,et al.  The 'healthy smoker': a phenomenon of health selection? , 1990, Respiration; international review of thoracic diseases.

[12]  D. Postma,et al.  Effect of 1-year smoking cessation on airway inflammation in COPD and asymptomatic smokers , 2005, European Respiratory Journal.

[13]  P. Anderson,et al.  Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial , 2001, The Lancet.

[14]  J. Pijoan,et al.  Predisposing factors to bacterial colonization in chronic obstructive pulmonary disease. , 1999, The European respiratory journal.

[15]  Phillips Yy,et al.  Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986. , 1987, The American review of respiratory disease.

[16]  W. Godwin.  Article in Press , 2000 .

[17]  B. Make,et al.  Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD , 2004, European Respiratory Journal.

[18]  X. Badia,et al.  [The Spanish version of EuroQol: a description and its applications. European Quality of Life scale]. , 1999, Medicina clinica.

[19]  W. Bailey,et al.  Effects of Smoking Intervention and the Use of an Inhaled Anticholinergic Bronchodilator on the Rate of Decline of FEV1 , 1994 .

[20]  M. Bartal.  COPD and tobacco smoke. , 2005, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

[21]  A. Buist.  Standardization of spirometry. , 1987, The American review of respiratory disease.

[22]  J. V. van Noord,et al.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium , 2002, European Respiratory Journal.

[23]  J. Hogg.  Why does airway inflammation persist after the smoking stops? , 2006, Thorax.

[24]  A. Buist.  Risk factors for COPD , 1996 .